questionText: To ask the Secretary of State for Health and Social Care, what evidence the Department has assessed on the average time from initiating a dopamine agonist, or increasing its dose, to (a) the onset or first report of impulse control disorder symptoms and (b) formal recognition and recording of dopamine agonist-associated impulse control disorders; and how those intervals vary by indication, care setting and method of detection.
answerText: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
heading: Drugs: Side Effects